Plain-English translation of NCT07023172 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →This is a real-world study of a medication called Proline Plus Empagliflozin that treats type 2 diabetes. Researchers want to learn how well this medication works and how safe it is when patients take it as part of their regular diabetes care. You would continue your normal diabetes treatment while the study team tracks how you respond.
Even after a medication is approved and available to patients, researchers need to study how it performs in everyday practice with many different people. This study will help doctors understand whether this medication works well for different types of patients and with different health conditions.
You likely qualify if…
You likely don't qualify if…
You would take the medication as prescribed by your doctor while the research team monitors your progress. You'll visit the clinic at the start, then at around 12 weeks, 24 weeks, and 48 weeks to have your blood sugar checked and answer questions about how you're doing. Some participants over age 50 may also complete brief memory and thinking tests. The study doesn't change your normal diabetes care—it simply watches and records how the medication works for you.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
China
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Enrollment target
~3,000 participants
Started
May 2025
Primary completion
October 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bi Yan
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.